State Street Corp Has $3.78 Million Holdings in XOMA Co. (NASDAQ:XOMA)

State Street Corp grew its position in XOMA Co. (NASDAQ:XOMA) by 1.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 142,857 shares of the biotechnology company’s stock after buying an additional 1,754 shares during the quarter. State Street Corp owned 1.21% of XOMA worth $3,783,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of New York Mellon Corp increased its stake in shares of XOMA by 3.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of XOMA by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 1,334 shares in the last quarter. Ellsworth Advisors LLC bought a new stake in shares of XOMA during the 3rd quarter valued at approximately $516,000. Finally, BNP Paribas Financial Markets increased its position in XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares in the last quarter. Institutional investors own 95.92% of the company’s stock.

XOMA Stock Performance

Shares of XOMA stock opened at $26.09 on Tuesday. The stock has a market capitalization of $307.42 million, a PE ratio of -7.50 and a beta of 0.88. XOMA Co. has a one year low of $18.57 and a one year high of $35.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The business’s 50 day simple moving average is $29.76 and its 200 day simple moving average is $27.87.

Insiders Place Their Bets

In other news, CEO Owen Hughes sold 21,881 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total transaction of $655,335.95. Following the transaction, the chief executive officer now owns 34,979 shares in the company, valued at approximately $1,047,621.05. This represents a 38.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on XOMA. StockNews.com lowered shares of XOMA from a “hold” rating to a “sell” rating in a research report on Friday. HC Wainwright restated a “buy” rating and set a $123.00 price objective on shares of XOMA in a research report on Friday, December 13th.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.